Can-Fite BioPharma (CANF) Competitors $1.02 -0.01 (-0.97%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$1.02 +0.00 (+0.49%) As of 07/3/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CANF vs. NKGN, CASI, SYBX, EDSA, CLRB, BFRG, ASBP, RLYB, FLGC, and ERNAShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include NKGen Biotech (NKGN), CASI Pharmaceuticals (CASI), Synlogic (SYBX), Edesa Biotech (EDSA), Cellectar Biosciences (CLRB), Bullfrog AI (BFRG), Aspire Biopharma (ASBP), Rallybio (RLYB), Flora Growth (FLGC), and Ernexa Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Its Competitors NKGen Biotech CASI Pharmaceuticals Synlogic Edesa Biotech Cellectar Biosciences Bullfrog AI Aspire Biopharma Rallybio Flora Growth Ernexa Therapeutics Can-Fite BioPharma (NYSE:CANF) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Which has stronger earnings & valuation, CANF or NKGN? Can-Fite BioPharma has higher revenue and earnings than NKGen Biotech. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$674K5.36-$7.63M-$1.79-0.57NKGen BiotechN/AN/A-$82.94M-$2.45-0.12 Which has more risk & volatility, CANF or NKGN? Can-Fite BioPharma has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Is CANF or NKGN more profitable? Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A NKGen Biotech N/A N/A -479.36% Do analysts rate CANF or NKGN? Can-Fite BioPharma currently has a consensus target price of $14.00, indicating a potential upside of 1,272.55%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, research analysts plainly believe Can-Fite BioPharma is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to CANF or NKGN? In the previous week, Can-Fite BioPharma had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for NKGen Biotech. Can-Fite BioPharma's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score. Company Overall Sentiment Can-Fite BioPharma Neutral NKGen Biotech Neutral Do institutionals & insiders hold more shares of CANF or NKGN? 21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCan-Fite BioPharma beats NKGen Biotech on 9 of the 13 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.61M$783.62M$5.49B$20.63BDividend YieldN/A4.84%5.38%3.75%P/E Ratio-0.571.3127.4228.08Price / Sales5.36220.40407.9745.89Price / CashN/A23.4436.6322.31Price / Book0.586.108.084.59Net Income-$7.63M-$27.81M$3.16B$985.44M7 Day Performance-1.45%0.82%2.81%2.78%1 Month Performance-8.11%8.15%3.68%5.41%1 Year Performance-57.85%7.78%35.29%14.61% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma2.7574 of 5 stars$1.02-1.0%$14.00+1,272.5%-57.9%$3.61M$674K-0.578NKGNNKGen BiotechN/A$0.33+37.4%N/A-77.3%$14.83MN/A-0.06N/ACASICASI Pharmaceuticals4.1382 of 5 stars$1.18-1.7%$4.00+239.0%-74.7%$14.76M$28.54M-0.46180Positive NewsHigh Trading VolumeSYBXSynlogic0.5432 of 5 stars$1.27+2.4%N/A-18.1%$14.50M$10K-0.5180Gap UpEDSAEdesa Biotech1.7743 of 5 stars$2.03-1.0%$5.00+146.3%-49.5%$14.40MN/A-1.2820Positive NewsCLRBCellectar Biosciences3.5552 of 5 stars$7.11-10.0%$375.00+5,174.3%-93.5%$14.30MN/A-0.3210Gap UpBFRGBullfrog AI1.0408 of 5 stars$1.51flatN/A+0.0%$14.22M$60K-1.864News CoveragePositive NewsASBPAspire BiopharmaN/A$0.27-5.4%N/AN/A$14.09MN/A0.00N/ARLYBRallybio2.0351 of 5 stars$0.34+1.6%$10.00+2,858.6%-73.6%$13.84M$640K-0.3140FLGCFlora Growth3.0608 of 5 stars$0.58-4.9%$4.00+589.7%-34.9%$13.77M$59.51M-0.59280News CoverageERNAErnexa Therapeutics0.677 of 5 stars$1.84-0.5%N/A-92.7%$13.62M$580K-0.2210Negative News Related Companies and Tools Related Companies NKGen Biotech Alternatives CASI Pharmaceuticals Alternatives Synlogic Alternatives Edesa Biotech Alternatives Cellectar Biosciences Alternatives Bullfrog AI Alternatives Aspire Biopharma Alternatives Rallybio Alternatives Flora Growth Alternatives Ernexa Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANF Stock Alerts